ALAina Llenas-Bladé

Aina Llenas-Bladé

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Aina Llenas-Bladé has a total of 36 co-authors. Here are the top co-authors by number of shared publications:

  • Jesús Brenes

    Department of Medical Oncology, Catalan Institute of Oncology (ICO), L'Hospitalet de Llobregat, Barcelona, 08908, Spain

    2 shared publications
  • Alicia Madurga

    Clinical Laboratory – Bellvitge University Hospital , L'Hospitalet de Llobregat , Barcelona , Spain

    1 shared publication
  • Ana Regina González-Tampán

    Clinical Nutrition Unit, Catalan Institute of Oncology (ICO), L’Hospitalet de Llobregat, Barcelona, Spain

    1 shared publication
  • Andrés Cuéllar

    Department of Medical Oncology, Institut Català d’Oncologia (ICO)- Hospital Duran i Reynals, L’Hospitalet de Llobregat, Barcelona, Spain

    1 shared publication
  • Anna Esteve

    Servei d'Oncologia Mèdica, Institut Català d'Oncologia (ICO), Badalona, Barcelona, Spain

    1 shared publication
  • Arturo Navarro-Martin

    Department of Radiation Oncology, Clínic Barcelona Villarroel 170, 08036 Barcelona, Spain

    1 shared publication

Latest Publications

  • Open Access

    Weight management in obese cancer patients during curative active treatment: protocol for the CANOBESE feasibility study

    by Aina Llenas-Bladé, Marta Puig Figueras, Carla Padilla Padilla, Anna Esteve, Raul Zamora-Ros, Mireia Daura i Vidal, Cristian Ochoa-Arnedo, Sonia Pernas, Cristina Santos Vivas, Jesús Brenes, et al.

    Obesity is highly prevalent among patients with cancer and is associated with increased risks of treatment-related complications, poorer oncological outcomes, and long-term morbidity. Despite this, current oncology nutrition guidelines primarily address malnutrition and provide limited direction for clinical management of patients with obesity. Intentional weight loss interventions during cancer treatment are uncommon, partly due to concerns about safety and feasibility. The CANOBESE study aims to address this evidence gap by evaluating the feasibility of implementing a structured, multimodal weight management programme for patients with obesity undergoing curative oncological treatment. This single-arm feasibility trial will recruit 50 adult patients with a BMI ≥ 30 kg/m2 and newly diagnosed stage II-IV solid tumours receiving chemotherapy, radiotherapy, immunotherapy, targeted therapy alone, or in combination with curative intent. The intervention includes a personalized hypocaloric and high-protein diet, a supervised home-based aerobic and resistance exercise programme, and integrated behavioural support delivered throughout the programme, with psycho-oncological input when more intensive individualized support is needed. Follow-up will continue for the duration of active treatment (3-9 months). The study will evaluate feasibility by examining key aspects such as recruitment and retention rates, intervention adherence and fidelity, participant acceptability, and the completeness of data collection throughout the intervention period. Secondary outcomes include exploratory changes in weight, body composition, physical performance, dietary intake, quality of life, and inflammatory biomarkers. The broad eligibility criteria were selected to evaluate feasibility in a pragmatic real-world oncology setting, while predefined exclusions were used to reduce baseline nutritional risk and improve safety. The CANOBESE study represents one of the first efforts to assess whether a comprehensive lifestyle intervention can be effectively delivered to patients with obesity during curative cancer treatment. This protocol incorporates patient and public involvement, a multidisciplinary team approach, and real-world implementation considerations. Findings will inform the scalability of the intervention, characterize implementation challenges across a pragmatic oncology population, and guide the design of a future randomized controlled trial. The study is not intended to provide subgroup-specific clinical recommendations, but to generate feasibility data that may help refine tailored approaches to intentional weight management in oncology settings. ClinicalTrials.gov identifier: NCT07058207. Registered on 9 July 2025. https://clinicaltrials.gov/study/NCT07058207.

  • Open Access

    Characterization of pretreatment cachexia through cytokine and nutritional analysis in patients with non-small cell lung carcinoma: the Marató cohort

    by Sara Hijazo-Pechero, Inmaculada Peiró, Lorena Arribas, Aina Llenas-Bladé, Felipe Jiménez, Joaquim Moreno-Caceres, Fedra Luciano-Mateo, Matías Fernández-Huarte, Nadia Gómez-Serra, Ana Regina González-Tampán, et al.

    Cancer cachexia is a frequent complication of patients diagnosed with non-small cell lung cancer (NSCLC) that affects their quality of life and their prognosis. A detailed, multidimensional characterization of patients with cancer cachexia is lacking. We conducted a prospective study of 52 patients diagnosed with locally advanced unresectable NSCLC who underwent concurrent chemoradiotherapy followed by immunotherapy. At baseline, 53% of patients met the Fearon’s criteria for cachexia. Cachexia was significantly associated with tumor stage (p < 0.001), performance status (p = 0.027), lower skeletal muscle index (p = 9e-4) and total adipose tissue index (p = 0.004), elevated C-Reactive Protein blood levels (p = 0.004), moderate to severe malnutrition (p < 0.001), reduced caloric intake (p = 0.007) and diminished physical strength (p = 0.001). Proteomic profiling using the O-link platform revealed known and novel biomarkers of cachexia, including inflammatory cytokines. Cachexia was significantly associated with elevated serum levels of CCL23, IL-6, CSF1, complement factor C1QA, motilin, agouti-related protein (AGRP) and soluble CD4 and CD276, and with lower RANKL, CKAP4, LRRN1, FLT3LG or Persephin, among others. These proteins showed varying degrees of correlation with caloric intake. GDF-15 was associated with weight loss (p = 0.00014), but not with cachexia (p=0.08), calorie intake or body composition. This prospective study demonstrates that cancer cachexia is highly prevalent in patients with unresectable locally advanced NSCLC and is associated with specific, understudied cytokines. These findings provide further insight into the biological characterization cachexia and may help identify novel targets for therapeutic interventions.